Recent Updates
Recently added Catalysts

GZ389988

Phase 2

Osteoarthritis | Small molecule | Musculoskeletal |Sanofi|Last Updated: Apr 13, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment132
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02845271Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the KneePHASE2 COMPLETED 104Jul 21, 2016Sep 13, 2017Apr 13, 20222 Germany
NCT02424942First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the KneePHASE1 COMPLETED 28Apr 1, 2015Jul 1, 2016Aug 17, 20161 Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change from baseline in weekly mean score of Western Ontario and McMaster Universities Arthritis Index (WOMAC) A1 pain subscore (walking pain) collected daily in the target knee, as measured by the Visual Analogue Scale (VAS) 0-100
Averaged over 4 weeks (up to Day 28)
Proportion of patients with adverse events
Up to Day 84 after single intraarticular dose of GZ389988
Proportion of patients with serious adverse events
12 additional weeks after day 84 (by phone calls)
Secondary Endpoints
Change from baseline in weekly mean score of WOMAC A1 pain sub-score (walking pain) collected daily in the target knee, as measured by the VAS 0-100
Averaged over 12 weeks (up to Day 84)
Change from baseline in weekly mean score of WOMAC A1 pain sub-score collected daily in the target knee
Averaged over 1, 2, 3, 6, 8, and 10 weeks
Change from baseline in weekly mean score of overall knee pain collected daily in the target knee
At and averaged over 1, 2, 3, 4, 6, 8, 10, and 12 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GZ389988EXPERIMENTALSingle intraarticular injection of GZ389988 in the knee joint
PlaceboPLACEBO_COMPARATORSingle intraarticular injection of placebo for GZ389988 in the knee joint
Interventions
NameTypeDescription
placeboDRUGPharmaceutical form:solvent for parenteral use Route of administration: intraarticular
GZ389988DRUGPharmaceutical form:suspension for injection Route of administration: intraarticular
acetaminophen or paracetamolDRUGPharmaceutical form: tablet Route of administration: oral
fixed combination of paracetamol + codeineDRUGPharmaceutical form: capsule Route of administration: oral
fixed combination of paracetamol + tramadol hydrochlorideDRUGPharmaceutical form: tablet Route of administration: oral
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion criteria : * Men or women 40 to 80 years of age. * Diagnosis of primary knee osteoarthritis (OA), based upon the following: * Fulfilling the American College of Rheumatology Clinical and Radiographic criteria for OA (at least knee pain and osteophytes), with * X-ray evidence within the la...

Countries:Germany
Unlock Eligibility Criteria